Junbo Ge, an academician of the Chinese Academy of Sciences, professor,  and doctoral supervisor, serves as a member of the Standing Committee of  the 14th National Committee of the Chinese People’s Political  Consultative Conference (CPPCC) and is the Vice Chairman of the Central  Committee of the Jiusan Society. He holds several prestigious positions  including Director of the Cardiology Department at Zhongshan Hospital  affiliated with Fudan University, President of Anhui Provincial  Hospital, Dean of the Biomedical Research Institute of Fudan University,  Director of the Shanghai Institute of Cardiovascular Diseases, Director  of the National Center for Clinical Research on Radiological and  Therapeutic Technology, and Director of the Ministry of Education’s  Engineering Research Center for Cardiovascular Interventions and  Devices. He is currently the President of the Cardiology Branch of the  Chinese Medical Doctor Association, Chairman of the China Cardiovascular  Health Alliance, Chairman of the China Chest Pain Center Alliance,  Executive Director of the Board of the World Heart Federation (WHF),  Honorary President of the 2nd Committee of the World Chinese  Cardiovascular Physicians Association, and serves as the Editor-in-Chief  of “Cardiology Plus,” Associate Editor of “Herz,” Deputy Editor of  “Chinese Journal of Cardiovascular Diseases,” and Deputy Editor of  “Chinese Journal of Interventional Cardiology.”

Academician Ge has long been committed to advancing major  cardiovascular disease diagnosis and treatment technologies and their  translation into practice in China, achieving many “firsts” in China and  the world in the field of cardiology. He was the first internationally  to identify specific echocardiographic diagnostic markers for myocardial  bridging, the “lunar phenomenon” and “fingertip phenomenon,” raising  the detection rate of myocardial bridging to over 95%. He pioneered the  “reverse wire technique” internationally, overcoming the “last bastion”  of complex coronary interventions. He was among the first in China to  perform selective coronary angiography. In 2006, he independently  developed the world’s first biodegradable drug-coated stent used in  clinical practice, breaking the price monopoly held by foreign  companies. In 2012, the launch of the arsenic trioxide stent marked the  only domestically produced stent with proprietary pharmaceutical rights  in China. In 2013, China’s first fully biodegradable stent was  introduced, leading the fourth revolution in coronary interventions in  China. He was among the first in the country to study and use artificial  bioprosthetic valves and to perform transapical aortic valve  implantation (TAVI) procedures. He pioneered the use of domestically  produced silk artificial blood vessels and is among the few in China to  perform thoracic endovascular aortic repair (TEVAR), holding the world’s  largest single-center sample for exploring extended and optimized TEVAR  strategies. He independently designed the adjustable FuStar sheath,  which has been industrialized.